Brief: Transgene, NEC Extend Collaboration On Clinical Development Of Neoantigen Cancer Vaccine TG4050

NEC

08/01/2024 16:49

Jan 8 (Reuters) - Transgene SA  TRNG.PA :
    * TRANSGENE AND NEC EXTEND THEIR COLLABORATION TO CONTINUE
JOINT
CLINICAL DEVELOPMENT OF NEOANTIGEN CANCER VACCINE TG4050
    * TRANSGENE AND NEC PLAN TO START AN EXTENSION OF RANDOMIZED
PHASE
I TRIAL INTO A RANDOMIZED PHASE I/II STUDY IN 2024 TO FURTHER
DEMONSTRATE POTENTIAL OF TG4050 AS AN ADJUVANT TREATMENT OF HEAD
AND NECK CANCERS
    * TG4050 IS CURRENTLY BEING EVALUATED IN A RANDOMIZED
MULTICENTER
PHASE I TRIAL AS A SINGLE AGENT IN ADJUVANT TREATMENT OF
HPV-NEGATIVE HEAD AND NECK CANCERS
    * TRANSGENE AND NEC EXPECT TO PRESENT ADDITIONAL
IMMUNOLOGICAL AND
CLINICAL DATA FROM PHASE I TRIAL AT A SCIENTIFIC CONFERENCE IN
FIRST HALF OF 2024

Source text for Eikon:  ID:nGNX1yfGpr 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))